TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15710812

Group type: EXPERIMENTAL
Intervention: Hypertonic saline-assisted LASEK (HS-LASEK)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Alcohol-assisted LASEK (A-LASEK)
Number of subjects: 52
Study: 12523867

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 100 mg/week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 200 mg/week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9155505

Group type: EXPERIMENTAL
Intervention: Selenomethionine (SeMet) 200 micrograms daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Selenate (Se-enriched yeast) 200 micrograms daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (no added Se)
Number of subjects: 36
Study: 8102542

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 70
Study: 3612550

Group type: EXPERIMENTAL
Intervention: Dopamine (5-100 micrograms/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Domperidone (0.4 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atropine, Phentolamine, Propranolol
Number of subjects: 12
Study: 31723064

Group type: EXPERIMENTAL
Intervention: Etokimab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29243443

Group type: EXPERIMENTAL
Intervention: CC+Gn+Dingkun Dan
Number of subjects: 60

Group type: COMPARATOR
Intervention: CC+Gn+HCG
Number of subjects: 60
Study: 27611776

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV)
Number of subjects: 209
Study: 25205409

Group type: EXPERIMENTAL
Intervention: US-guided single-injection femoral nerve block with 40 ml of 0.5% bupivacaine and 1:200,000 epinephrine (Group F)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Preservative-free saline (Group P)
Number of subjects: 104
Study: 23060723

Group type: EXPERIMENTAL
Intervention: Macular laser photocoagulation following intravitreal injection of triamcinolone acetonide (IVTA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravitreal injection of triamcinolone acetonide (IVTA) alone
Number of subjects: 74
Study: 20214324

Group type: EXPERIMENTAL
Intervention: Serial gout granules (SGGs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac sodium dual release enteric-coated capsules and Benzbromarone (Control)
Number of subjects: 60
Study: 17855709

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI) at baseline
Number of subjects: 286

Group type: COMPARATOR
Intervention: Lower body mass index (BMI) at baseline
Number of subjects: 286
Study: 14985171

Group type: EXPERIMENTAL
Intervention: Platelet-neutrophil conjugate formation induced by thrombin receptor activating peptide (TRAP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Troponin I levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platelet aggregation (induced by ADP and arachidonic acid)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TRAP-induced platelet-neutrophil conjugate formation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platelet-neutrophil conjugates
Number of subjects: 30
Study: 11434167

Group type: EXPERIMENTAL
Intervention: Children with IgA nephropathy (IgA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Children with Schönlein-Henoch purpura (Sch-H)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (21 healthy children)
Number of subjects: 21
Study: 9596049

Group type: EXPERIMENTAL
Intervention: Intensive psychiatric community care (IPCC) at general medical and surgical sites
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Intensive psychiatric community care (IPCC) at neuropsychiatric sites
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard Department of Veterans Affairs care at general medical and surgical sites
Number of subjects: 271

Group type: COMPARATOR
Intervention: Standard Department of Veterans Affairs care at neuropsychiatric sites
Number of subjects: 271
Study: 7512299

Group type: COMPARATOR
Intervention: Three TUHT treatments
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Six TUHT treatments
Number of subjects: 28
Study: 2905803

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (5 or 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic BZ users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmedicated anxious subjects
Number of subjects: 0
Study: 1320621

Group type: EXPERIMENTAL
Intervention: 1.5 mm intramedullary rod (polyglycolide implants)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kirschner wire
Number of subjects: 0
Study: 82735

Group type: EXPERIMENTAL
Intervention: Enkephalin analogue [D‐Ala2, MePhe4, Met(o)‐ol] enkephalin (DAMME) administered intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior administration of the opiate antagonist, naloxone
Number of subjects: 0
Study: 31014112

Group type: EXPERIMENTAL
Intervention: Narrative message emphasizing external factors while acknowledging personal responsibility
Number of subjects: 5007

Group type: COMPARATOR
Intervention: Magnitude of problem message (comparison group 1)
Number of subjects: 5007

Group type: COMPARATOR
Intervention: Magnitude of problem and inoculation messages (comparison group 2)
Number of subjects: 5007

Group type: EXPERIMENTAL
Intervention: Counter message emphasizing personal responsibility
Number of subjects: 5007
Study: 31203241

Group type: EXPERIMENTAL
Intervention: Molidustat (starting dose 75 mg/day, titrated 4-weekly)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Darbepoetin alfa (control)
Number of subjects: 300
Study: 28261923

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy (iCBT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Monitored waitlist control
Number of subjects: 65
Study: 26209233

Group type: EXPERIMENTAL
Intervention: 23 gauge vitrectomy, endolaser, and gas tamponade (Group 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 23 gauge vitrectomy alone (Group 2)
Number of subjects: 16
Study: 23250189

Group type: EXPERIMENTAL
Intervention: SLE plus clinical immersion (RCT 1: 1 week SLE before 3 weeks clinical immersion)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: SLE plus clinical immersion (RCT 2: 2 weeks interspersed SLE/clinical immersion)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Clinical immersion (control group)
Number of subjects: 349
Study: 21303403

Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin (AMX) 500mg + metronidazole (MET) 250mg, t.i.d. for 10 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 19246731

Group type: EXPERIMENTAL
Intervention: PEG-TPOm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17122107

Group type: EXPERIMENTAL
Intervention: 2.5 mg lutein
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg lutein
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 mg lutein
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All doses of lutein
Number of subjects: 45
Study: 15086634

Group type: EXPERIMENTAL
Intervention: Falls Prevention Programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control graphs
Number of subjects: 0
Study: 11401883

Group type: EXPERIMENTAL
Intervention: CNEP (‐5 cm H(2)O)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NPV
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NPV plus NEEP
Number of subjects: 7

Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 7
Study: 9203079

Group type: EXPERIMENTAL
Intervention: Prestimulus EEG microstate (oriented left anterior-right posterior)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prestimulus EEG microstate (right anterior-left posterior)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Post-stimulus ERP microstates
Number of subjects: 12
Study: 8352217

Group type: EXPERIMENTAL
Intervention: PRP-T vaccine
Number of subjects: 484

Group type: COMPARATOR
Intervention: HbOC vaccine
Number of subjects: 484
Study: 2962529

Group type: EXPERIMENTAL
Intervention: Thiamphenicol 2.5 g orally
Number of subjects: 207

Group type: COMPARATOR
Intervention: Spectinomycin 2 g intramuscularly
Number of subjects: 207
Study: 31265205

Group type: EXPERIMENTAL
Intervention: Subperception spinal cord stimulation (SCS) at ≤1.2 kHz
Number of subjects: 140

Group type: COMPARATOR
Intervention: Supraperception spinal cord stimulation (SCS)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Subperception spinal cord stimulation (SCS) at 12 months post-activation
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Multiple waveform options
Number of subjects: 140
Study: 30124744

Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Functional capacity (FC) assessment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Clinical symptoms assessment
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Self-reported disability assessment
Number of subjects: 96
Study: 28406862

Group type: EXPERIMENTAL
Intervention: IV hydrocortisone
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 25604154

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 20
Study: 24094979

Group type: EXPERIMENTAL
Intervention: Standard care plus cognitive-behavioral therapy (STD + CBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard conservative care (STD)
Number of subjects: 101
Study: 21602025

Group type: EXPERIMENTAL
Intervention: Muscle‐sparing group (modified Watson‐Jones approach)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mini‐incision direct lateral group (control)
Number of subjects: 102
Study: 18430857

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (healthy population)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Probable Alzheimer's disease
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Possible Alzheimer's disease
Number of subjects: 95
Study: 16517051

Group type: EXPERIMENTAL
Intervention: ZD0947 (25mg/day for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12243656

Group type: EXPERIMENTAL
Intervention: 10 cc of 2% intrarectal lidocaine gel (Xylocaine 2% jelly, Astra Pharma Inc.) 5 to 10 minutes before the procedure
Number of subjects: 360

Group type: COMPARATOR
Intervention: 10 cc of lubricating gel
Number of subjects: 360
Study: 10652641

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNFα blockade
Number of subjects: 0
Study: 7593073

Group type: EXPERIMENTAL
Intervention: Magnetic resonance venography
Number of subjects: 45

Group type: COMPARATOR
Intervention: Contrast venography
Number of subjects: 45
Study: 2305099

Group type: EXPERIMENTAL
Intervention: 30 mL of contrast material injected at the level of the external iliac artery (EIA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 60 mL of contrast material injected at the level of the EIA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 120 mL of contrast material injected at the level of the aortic bifurcation and 60 mL injected at the level of the EIA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 60 mL injected at the level of the EIA with inflow occlusion
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 60 mL injected at the level of the EIA without inflow occlusion
Number of subjects: 52
Study: 7005123

Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Furosemide + Triamterene (80 + 100 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 28338504

Group type: EXPERIMENTAL
Intervention: Protective group (tidal volume; 6 mL/kg predicted body weight, 6 cm H2O positive end-expiratory pressure with recruitment maneuvers)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional group (10 mL/kg predicted body weight, no positive end-expiratory pressure)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Protective group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 78
Study: 26657997

Group type: EXPERIMENTAL
Intervention: 15-mcg unadjuvanted clade 2 vaccine
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 90-mcg unadjuvanted clade 2 vaccine
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 90-mcg dosage in unprimed recipients
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Clade 1 stimulation
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Clade 2 stimulation
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted clade 1 H5N1 vaccines
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted clade 1 H5N1 vaccines
Number of subjects: 177
Study: 24651512

Group type: EXPERIMENTAL
Intervention: Strengthening exercises (STRE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Flexibility exercises (FLEX)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (STRE and FLEX)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Strengthening exercises (STRE) and Flexibility exercises (FLEX)
Number of subjects: 80
Study: 22584689

Group type: EXPERIMENTAL
Intervention: Lornoxicam 16 mg then 8 mg after 12 h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g every 6 h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 60
Study: 21097402

Group type: EXPERIMENTAL
Intervention: Shuganlipi decoction
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine western medication
Number of subjects: 86
Study: 17277593

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Single Resistance Exercise (RE) bout
Number of subjects: 11

Group type: COMPARATOR
Intervention: Resistance Exercise (RE) before ST
Number of subjects: 11

Group type: COMPARATOR
Intervention: Resistance Exercise (RE)
Number of subjects: 11
Study: 16254092

Group type: EXPERIMENTAL
Intervention: Belief in meritocracy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disbelief in meritocracy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Belief in meritocracy (control condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disbelief in meritocracy (control condition)
Number of subjects: 0
Study: 12374324

Group type: EXPERIMENTAL
Intervention: Mesencephalic dopamine system for reinforcement learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic error-processing system associated with the anterior cingulate cortex
Number of subjects: 0
Study: 9935005

Group type: EXPERIMENTAL
Intervention: Biphasic shocks at 5 seconds of VF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biphasic shocks at 10 seconds of VF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biphasic shocks at 20 seconds of VF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Increase in DFT observed in patients
Number of subjects: 30
Study: 7766740

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 242
Study: 2148177

Group type: EXPERIMENTAL
Intervention: cetirizine 5 mg, 10 mg, or 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hydroxyzine 25 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 7440519

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 184

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 31959151

Group type: EXPERIMENTAL
Intervention: Psychosocial support group intervention
Number of subjects: 742

Group type: COMPARATOR
Intervention: Improved standard of mental health care
Number of subjects: 742
Study: 30632972

Group type: EXPERIMENTAL
Intervention: BlueStar mobile app for 6 months (immediate treatment group)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care for 3 months followed by BlueStar mobile app for 3 months (wait-list control group)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Exploratory analysis of app usage
Number of subjects: 223
Study: 28759262

Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 25754454

Group type: EXPERIMENTAL
Intervention: Intravesical 0.1% oxybutynin hydrochloride (10 ml, three times per day for 28 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral 5 mg oxybutynin hydrochloride (three times per day for 28 days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravesical 0.1% oxybutynin hydrochloride
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral 5 mg oxybutynin hydrochloride
Number of subjects: 35
Study: 25031529

Group type: EXPERIMENTAL
Intervention: Alpha-blocker plus antidiuretic agent
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Alpha-blocker plus anticholinergic agent
Number of subjects: 405

Group type: COMPARATOR
Intervention: Alpha-blocker
Number of subjects: 405
Study: 22367233

Group type: EXPERIMENTAL
Intervention: Sleep Education Program (SEP)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 47
Study: 19085703

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 94
Study: 17134951

Group type: EXPERIMENTAL
Intervention: Enriched eggs (5 per week for 3 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal eggs (5 per week for 3 weeks)
Number of subjects: 25
Study: 16363623

Group type: EXPERIMENTAL
Intervention: Lacrimal scintigraphy in patients with dry eye syndrome
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lacrimal scintigraphy in normal subjects
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Schirmer‐1 test in patients with dry eye syndrome
Number of subjects: 21

Group type: COMPARATOR
Intervention: Schirmer‐1 test in normal subjects
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BUT in patients with dry eye syndrome
Number of subjects: 21

Group type: COMPARATOR
Intervention: BUT in normal subjects
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Rose bengal staining in patients with dry eye syndrome
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rose bengal staining in normal subjects
Number of subjects: 21
Study: 12412821

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg/5 min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (all doses)
Number of subjects: 36
Study: 10030179

Group type: EXPERIMENTAL
Intervention: Slide-tape with information on postoperative rehabilitation
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Training in Benson's Relaxation Response with bedside audiotape
Number of subjects: 222
Study: 1519474

Group type: EXPERIMENTAL
Intervention: Atraumatic Sprotte needle (22G)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sharp Quincke needle (22G)
Number of subjects: 75
Study: 6388080

Group type: EXPERIMENTAL
Intervention: Noradrenaline (8 mg in 100 ml cold saline)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cold saline alone
Number of subjects: 42
Study: 31748905

Group type: EXPERIMENTAL
Intervention: Radiotherapy with pentoxifylline and vitamin E
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy (control group)
Number of subjects: 60
Study: 28919128

Group type: EXPERIMENTAL
Intervention: Pregabalin (≤600mg/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26818372

Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 54
Study: 25335245

Group type: EXPERIMENTAL
Intervention: Acupuncture at stellate ganglion (observation group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional acupuncture (control group)
Number of subjects: 80
Study: 22521705

Group type: EXPERIMENTAL
Intervention: Resin‐modified GIC (RM‐GIC) open laminate plus resin composite
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Conventional GIC open laminate plus resin composite
Number of subjects: 24

Group type: COMPARATOR
Intervention: Resin composite alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laminate restorations
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Conventional GIC
Number of subjects: 24
Study: 19763661

Group type: COMPARATOR
Intervention: Post-PCI TIMI flow grade 1
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI flow grade 0
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Post-PCI TIMI flow grade 2
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Post-PCI TIMI flow grade 3
Number of subjects: 1761
Study: 19067804

Group type: EXPERIMENTAL
Intervention: Younger women (<50 years old)
Number of subjects: 88
Study: 16650725

Group type: EXPERIMENTAL
Intervention: Letter Memory Test (LMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letter Memory Test (LMT) with difficulty manipulations
Number of subjects: 0
Study: 12784167

Group type: EXPERIMENTAL
Intervention: Coronary artery disease patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 22
Study: 10858991

Group type: EXPERIMENTAL
Intervention: CM challenge after 12 months of CM-free diet
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CM challenge
Number of subjects: 86

Group type: COMPARATOR
Intervention: Immunologic tests (IgE, RAST, cutaneous prick tests)
Number of subjects: 86